An observational study to evaluate the effect of body surface area on survival of patients with epidermal growth factor receptor (EGFR)-mutant non small cell lung cancer treated with gefitinib: Okayama Lung Cancer Study Group 0703

Trial Profile

An observational study to evaluate the effect of body surface area on survival of patients with epidermal growth factor receptor (EGFR)-mutant non small cell lung cancer treated with gefitinib: Okayama Lung Cancer Study Group 0703

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top